These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Bilateral extensive lesions of the brain in a patient with neuromyelitis optica manifested with seizure and cognitive impairments. Naser Moghadasi A Rev Neurol (Paris); 2019 Apr; 175(4):272-274. PubMed ID: 30879604 [No Abstract] [Full Text] [Related]
44. Intravenous Immunoglobulin Therapy in a Patient With Anti-Myelin Oligodendrocyte Glycoprotein-Seropositive Neuromyelitis Optica. Domingo-Santos Á; Sepúlveda M; Matarazzo M; Calleja-Castaño P; Ramos-González A; Saiz A; Benito-León J Clin Neuropharmacol; 2016; 39(6):332-334. PubMed ID: 27454390 [No Abstract] [Full Text] [Related]
45. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. Cabre P; Mejdoubi M; Jeannin S; Merle H; Plumelle Y; Cavillon G; Smadja D; Marignier R; J Neurol; 2018 Apr; 265(4):917-925. PubMed ID: 29455361 [TBL] [Abstract][Full Text] [Related]
46. Anti-N-methyl-d-aspartate receptor encephalitis in a patient with neuromyelitis optica spectrum disorders. Luo JJ; Lv H; Sun W; Zhao J; Hao HJ; Gao F; Huang YN Mult Scler Relat Disord; 2016 Jul; 8():74-7. PubMed ID: 27456878 [TBL] [Abstract][Full Text] [Related]
47. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID). Rommer PS; Dörner T; Freivogel K; Haas J; Kieseier BC; Kümpfel T; Paul F; Proft F; Schulze-Koops H; Schmidt E; Wiendl H; Ziemann U; Zettl UK; J Neuroimmune Pharmacol; 2016 Mar; 11(1):1-8. PubMed ID: 26589235 [TBL] [Abstract][Full Text] [Related]
48. Immune agents for the treatment of Devic's neuromyelitis optica. Bergamaschi R Neurol Sci; 2007 Oct; 28(5):238-40. PubMed ID: 17972036 [No Abstract] [Full Text] [Related]
49. Use of intravenous immunoglobulin in toxic epidermal necrolysis. Feldmeyer L; Kerdel FA; French LE Arch Dermatol; 2011 Dec; 147(12):1440-1. PubMed ID: 22184768 [No Abstract] [Full Text] [Related]
50. Intravenous immunoglobulin therapy: the process, the product, the patient, and the pocketbook. Introduction. Harvey RD Pharmacotherapy; 2005 Nov; 25(11 Pt 2):71S-72S. PubMed ID: 16229676 [No Abstract] [Full Text] [Related]
51. [Use of intravenous immunoglobulin in neurological disorders]. Steck AJ Rev Med Suisse; 2005 Apr; 1(17):1167-70. PubMed ID: 15941089 [TBL] [Abstract][Full Text] [Related]
52. Comment on "Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin". Buenz EJ J Clin Neurosci; 2009 Aug; 16(8):1110; author reply 1111. PubMed ID: 19467870 [No Abstract] [Full Text] [Related]
53. To use or not to use? Polyclonal intravenous immunoglobulins for the treatment of sepsis and septic shock. Neugebauer EA Crit Care Med; 2007 Dec; 35(12):2855-6. PubMed ID: 18043203 [No Abstract] [Full Text] [Related]
54. Summaries for patients: Intravenous immunoglobulin treatment of the complex regional pain syndrome. Ann Intern Med; 2010 Feb; 152(3):I48. PubMed ID: 20124227 [No Abstract] [Full Text] [Related]
55. Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Weinstock-Guttman B; Miller C; Yeh E; Stosic M; Umhauer M; Batra N; Munschauer F; Zivadinov R; Ramanathan M Mult Scler; 2008 Sep; 14(8):1061-7. PubMed ID: 18573816 [TBL] [Abstract][Full Text] [Related]
56. Should intravenous immunoglobulin be given to patients with postoperative chylothorax? McMullan DM Pediatr Crit Care Med; 2012 Sep; 13(5):599-600. PubMed ID: 22955461 [No Abstract] [Full Text] [Related]
57. A dramatic response to intravenous immunoglobulin in a patient with mixed cryoglobulinemia. Almog O; Berlin T; Rotman-Pikielny P; Levy Y Isr Med Assoc J; 2010 Jan; 12(1):53-4. PubMed ID: 20450133 [No Abstract] [Full Text] [Related]